公开(公告)号：US20190389936A1

公开(公告)日：2019-12-26

申请号：US16475955

申请日：2018-01-04

Applicant: Kyungpook National University Industry-Academic Cooperation Foundation ,  Korea Institute of Science and Technology

Inventor： So Youn Kim ,  Jun Young Seo ,  In San Kim

IPC: C07K14/79 ,  A61K47/66 ,  C07K7/06

Abstract: The present invention relates to: a fusion peptide comprising a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide; and a use thereof and, more specifically, to: a fusion peptide in which a thrombus-targeting peptide, ferritin fragment and a thrombolytic peptide are sequentially linked; a composition for preventing or treating thrombotic disorders, containing the same as an active ingredient; a method for treating thrombotic disorders; and a therapeutic use. According to the present invention, CLT-sFt-μPn DCNC as a novel plasmin-based thrombolytic nanocage has: an effect of targeting a site at which thrombus is present; a low sensitivity to inhibitors present in the circulatory system; pharmacological activity strongly destroying both arterial and venous thrombi; and no side effects of bleeding, and thus can be very useful in developing an agent for preventing or treating thrombotic disorders.

公开(公告)号：US20170183416A1

公开(公告)日：2017-06-29

申请号：US15363103

申请日：2016-11-29

Applicant: SEOUL NATIONAL UNIVERSITY ,  UNIVERSITY OF ULSAN ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  PHARSOGEN

Inventor： Youngro Byun ,  In San Kim ,  Ahmed Al-Hilal Taslim ,  Sang-Yoon Kim ,  Ye Ji Jang

IPC: C07K16/28 ,  G01N33/574 ,  G01N33/68 ,  A61K31/727

CPC classification number: C07K16/2872 ,  A61K31/727 ,  A61K39/3955 ,  A61K47/554 ,  C07K14/705 ,  C07K16/18 ,  C07K16/28 ,  C07K2317/14 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/3515 ,  G01N33/57492 ,  G01N33/6893 ,  G01N2333/705

Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.

公开(公告)号：US09409923B2

公开(公告)日：2016-08-09

申请号：US13936768

申请日：2013-07-08

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Kwang Meyung Kim ,  Ick Chan Kwon ,  Sang Yoon Kim ,  Ju Hee Ryu ,  Eun Sung Jun ,  In San Kim

IPC: C07D499/78 ,  C07D209/62 ,  C07D409/14 ,  C07D498/08

CPC classification number: C07D499/78 ,  C07D209/62 ,  C07D409/14 ,  C07D498/08

Abstract: Disclosed is a drug-fluorophore complex for specific detection of tumor cells. Specifically, the drug-fluorophore complex includes a tumor cell-targeting drug penetrating tumor cells and non-tumor cells at different rates or levels, and a fluorescent substance chemically bonded to the tumor cell-targeting drug. The drug-fluorophore complex enables specific imaging of tumor cells only with high accuracy in a very simple manner without causing cytotoxicity.

Abstract translation: 公开了用于特异性检测肿瘤细胞的药物 - 荧光团复合物。 具体地，药物 - 荧光团复合物包括以不同速率或水平渗透肿瘤细胞和非肿瘤细胞的肿瘤细胞靶向药物和与肿瘤细胞靶向药物化学键合的荧光物质。 药物荧光团复合物能够以非常简单的方式以高精度进行肿瘤细胞的特异性成像，而不引起细胞毒性。

公开(公告)号：US10202459B2

公开(公告)日：2019-02-12

申请号：US15363103

申请日：2016-11-29

Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION ,  UNIVERSITY OF ULSAN ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  PHAROSGEN

Inventor： Youngro Byun ,  In San Kim ,  Ahmed Al-Hilal Taslim ,  Sang-Yoon Kim ,  Ye Ji Jang

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/28 ,  A61K31/727 ,  G01N33/574 ,  G01N33/68 ,  C07K14/705 ,  C12N15/113 ,  A61K47/54

Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.

公开(公告)号：US20170260278A1

公开(公告)日：2017-09-14

申请号：US15450272

申请日：2017-03-06

Applicant: SEOUL NATIONAL UNIVERSITY ,  UNIVERSITY OF ULSAN ,  KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY ,  PHAROSGEN

Inventor： Youngro Byun ,  In San Kim ,  Ahmed Al-Hilal Taslim ,  Sang-Yoon Kim ,  Ye Ji Jang

IPC: C07K16/28

CPC classification number: C07K16/2872 ,  A01K2217/075 ,  A01K2227/105 ,  A61K47/55 ,  A61K47/554 ,  A61K47/61 ,  A61K2039/505 ,  A61P35/00 ,  C07K16/30 ,  C07K2317/70 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/113 ,  C12N2310/11 ,  C12N2310/3515 ,  C12Q1/68 ,  G01N33/57492 ,  G01N33/6893 ,  G01N2333/705

Abstract: Described herein are doppel-targeting molecules useful for inhibiting pathological angiogenesis and treating diseases and conditions associated with pathological angiogenesis, such as tumors, cancers, atherosclerosis, tuberculosis, asthma, pulmonary arterial hypertension (PAH), neoplasms and neoplasm-related conditions, and for detecting doppel expression in a subject. Related compositions and methods also are described.